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have a lower risk of most cancers. Jet lag symptoms are heterogeneous. Therefore,
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The mechanistic chain between in vitro and in vivo treatment effects has weak links,
especially between circadian rhythm disruption in animals and the improvement of jet
lag symptoms in humans. While the number of animal studies has increased
exponentially between 1990 and present, only 1-2 randomised controlled trials on jet
lag treatments are published every year. There is one relevant Cochrane review, in
which only 2-4 studies on melatonin, without baseline measures, were meta-analysed.
Study effect sizes reduced substantially between 1987, when the first paper on
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greater number of human randomised controlled trials would provide a firmer platform
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Summary 
Recent laboratory experiments on rodents have increased our understanding of 
circadian rhythm mechanisms. Typically, circadian biologists attempt to translate 
their laboratory-based findings to treatment of jet lag symptoms in humans. We 
aimed to scrutinise the strength of the various links in the translational pathway from 
animal model to human traveller. First, we argue that the translation of findings from 
pre-clinical studies to effective jet lag treatments and knowledge regarding longer-
term population health is not robust, e.g., the association between circadian 
disruption and cancer found in animal models does not translate well to cabin crew 
and pilots, who have a lower risk of most cancers. Jet lag symptoms are 
heterogeneous. Therefore, the true prevalence and the effects of any intervention 
are difficult to quantify precisely. The mechanistic chain between in vitro and in vivo 
treatment effects has weak links, especially between circadian rhythm disruption in 
animals and the improvement of jet lag symptoms in humans. While the number of 
animal studies has increased exponentially between 1990 and present, only 1-2 
randomised controlled trials on jet lag treatments are published every year. There is 
one relevant Cochrane review, in which only 2-4 studies on melatonin, without 
baseline measures, were meta-analysed. Study effect sizes reduced substantially 
between 1987, when the first paper on melatonin was published, and 2001. We 
suggest that knowledge derived from a greater number of human randomised 
controlled trials would provide a firmer platform for circadian biologists to cite jet lag 
treatment as an important application of their findings. 
 
Key words: Evidence translation; External validity; Mechanistic research; 
Randomised controlled trials 
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Introduction 
Recent laboratory-based experiments have furthered our understanding of circadian 
biology. For example, in a recent study entitled “Vasopressin V1a and V1b receptors 
are resistant to jet lag”, it was reported that pharmacological blockade of vasopressin 
receptors in the suprachiasmatic nuclei of wild-type mice accelerates the adjustment 
of circadian timing following shifts of the light dark cycle (Yamaguchi et al. 2013). 
Therefore, Yamaguchi et al. (2013) postulated that vasopressin signalling could be a 
target for treating jet lag. In an accompanying commentary, it was stated that “Jet lag 
is a blessing to circadian biologists because the disruption of mental and physical 
well-being immediately highlights the importance of our internal body clock” 
(Hastings 2013). Nevertheless, it was also noted by Hastings (2013) that, at present, 
there is no cure for jet lag. 
 
Basic mechanistic experiments like the one undertaken by Yamaguchi et al. (2013) 
constitute the first step in the physiological translational pathway (Seals 2013). This 
pathway can be made specific to jet lag research (Figure 1). The first translational 
step moves from the results of animal experiments on basic circadian biology to 
human circadian physiology. There are two other translational steps. Findings from 
experiments on human circadian physiology need to translate adequately to clinical 
practice, which, in the present context, includes jet lag treatments for populations 
that are viewed to benefit from clinical intervention, e.g., airline pilots. These findings 
then need to translate to longer-term population health, e.g., whether transmeridian 
flights are associated with an increased risk of cancer. The pathway is a bidirectional 
closed loop where information can translate through translational steps one to three, 
or from steps three to one. This latter type of translational research where population 
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level studies might inform how basic research is undertaken has been termed, 
“reverse translation” (Seals 2013). 
 
Typically, circadian biologists, who examine the adjustment of animal circadian 
rhythms in response to changes in laboratory conditions, suggest that their findings 
will translate to proposed treatments for jet lag and/or shift work disorder, i.e. from 
translation steps one to two/three. Because millions of people fly across time zones 
every year, new studies that are relevant to jet lag can generate considerable 
interest. Sometimes, the translation of pre-clinical findings from laboratory-based 
experiments on rodents can be somewhat overhyped in the media, e.g., 
http://www.bbc.co.uk/news/health-23880152. Furthermore, recent developments in 
technology have meant that people can now easily access advice about jet lag. For 
example, predominantly theoretical models of the human circadian pacemaker 
(Forger et al. 1999) have been translated by mathematicians to a Smartphone-based 
App called Entrain. This software is designed to improve jet lag symptoms by 
supplying advice regarding timing of light exposure on each day after the flight, 
http://entrain.math.lsa.umich.edu/.  
 
It is clear that jet lag is of interest to both basic circadian biologists and applied 
researchers who want to use mechanistic information to develop effective treatments 
for jet lag. In the present review, we discuss several fundamental questions that 
arise in this causal pathway between animal and human traveller. These questions 
are informed by the checklist for using mechanistic research to justify extrapolation 
of study results to target human populations (Howick et al. 2013); 
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1. What is jet lag and how is it measured? 
2. In which population is jet lag clinically important enough to treat, and does this 
population differ from those studied by researchers? 
3. What  is the evidence that the proposed treatments are effective in reducing 
jet lag symptoms following transmeridian travel? 
3.4. Does the evidence from animal experiments on circadian rhythm 
disruption translate to population health research? 
 
1. What is jet lag and how is it measured? 
The conceptualisation and, consequently, the published definitions of jet lag can vary 
in terms of the relative focus on jet lag symptoms and/or the misalignment of 
circadian rhythms. For example, Samuels (2012) defined jet lag as “a syndrome of 
symptoms manifested by physiologic adaptations that occur when the body is shifted 
into a new time zone”. Nevertheless, it is clear from some of the study titles in the 
literature that measurement of the adjustment of circadian rhythms of animals per se 
is also referred to as jet lag. For example, Yamaguchi et al. (2013) modelled jet lag 
on the basis of a nocturnal animal delaying their initiation of activity in response to a 
change in the timing of lights-off. This interchangeable use of the term jet lag is not 
particularly helpful, since it relies on the assumption of a robust correlation between 
measured changes in circadian rhythm timing in either animals or humans and overt 
jet lag symptoms, which cannot be measured directly in animal models. 
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The strength of the correlation between changes in circadian timing and jet lag 
symptoms is rather unclear at present. Sack (2010) suggested that the circadian 
timing of the melatonin rhythm adjusts approximately 1 hour per day following an 
eastwards flight. Nevertheless, people travelling over 1-3 time zones tend to 
experience negligible symptoms of jet lag (Waterhouse et al. 2007), suggesting non-
linearity in the correlation between rhythm adjustment and symptoms. Moreover, this 
estimate of daily circadian adjustment would mean that it takes approximately 10 
days for circadian rhythms to adjust completely following an easterly flight across 10 
time zones, e.g., from the UK to eastern Australia. In contrast, data from Edwards et 
al (2000) indicated that the various symptoms of jet lag are negligible (<0.5 on a 0-10 
simple analogue scale) six days after such a flight. 
 
Jet lag symptoms are clearly caused by circadian rhythm disruption following a flight 
across time zones. But the study of the causal pathway between circadian rhythm 
disruption and jet lag symptoms is confounded by a myriad of other human and 
environmental factors, which impinge on post-flight feelings. Although these overt 
feelings are influenced by circadian rhythm disruption, there is no strong evidence to 
indicate that the rate of circadian rhythm adjustment per se can be used as a reliable 
proxy for jet lag symptoms in humans. This is notwithstanding the fact that jet lag 
symptoms are the fundamental outcomes to be treated and may be easier to 
measure and monitor than some circadian rhythms (e.g. salivary melatonin) during a 
post-flight period. 
 
As highlighted in previous reviews (Waterhouse et al. 1997; Waterhouse et al. 2007; 
Sack 2010), the measurement of jet lag symptoms is extremely complicated. Not 
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surprisingly, there is marked variation in the types and severity of jet lag symptoms 
both between- and within-individuals over the course of the post-flight period 
(Waterhouse et al. 1997; Waterhouse et al. 2007; Sack 2010). For global jet lag 
ratings on a 0-100 scale, the between-subjects standard deviation often exceeds 
90% of the sample mean (Herxheimer and Petrie, 2002). This between-subjects 
coefficient of variation reflects an extraordinarily large inter-individual heterogeneity 
in overall jet lag perception. Heterogeneity is also apparent in the types of symptoms 
experienced. These symptoms of sleepiness, insomnia, clumsiness, headache, 
gastro-intestinal disturbances are not specific to jet lag and can vary in their degree 
of association with the overall construct of jet lag (Waterhouse et al. 2002).   
 
Despite the availability of measurement tools which focus on multiple symptoms 
(Waterhouse et al. 2002; Spitzer et al. 1999), there is currently no uniform approach 
to the measurement of jet lag symptoms. Researchers tend to select different 
primary outcomes for indicating jet lag severity. Herzheimer and Petrie (2002) were 
able to meta-analyse only 2-4 of the 10 studies on melatonin that met the inclusion 
criteria for a systematic review. This was after the data from two of these studies 
(Claustrat et al. 1992; Nicholson et al. 1991) needed to be converted to the selected 
common outcome of the overall perception of jet lag on a 0-100 scale. The 
systematic review by Herxheimer and Petrie (2002) is discussed in more detail in 
section 3. 
 
2. Is jet lag clinically important for everyone? 
The extent to which any jet lag symptoms are considered to be debilitating differs 
greatly between individuals, ranging from the mild inconvenience experienced by 
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tourists, to the potential compromising effects of frequent flying across time zones on 
vigilance and functioning outcomes in military and non-military flight crews. This 
latter population has to cope with both advance/delay and delay/advance events, 
usually with only 1-2 days at destination, which is all very difficult to simulate in the 
laboratory. A popular protocol for modelling jet lag symptoms in animal experiments 
is an 8-h advance of the light-dark cycle every two days over a 10-day period 
(Filipski et al., 2004). When translated to human pilots and cabin crew, this protocol 
would equate to the undertaking of five westerly flights, each being approximately 9-
13 hours in duration, and all being undertaken within a 10 day period. This degree of 
circadian disruption would be extremely unusual for non-military pilots and crew. 
 
Another target population for jet lag treatments is athletes (Reilly et al., 2001), but 
the clinical relevance of jet lag can depend on the athlete’s competitive standard. 
Although world-class athletes clearly report symptoms of jet lag following 
transmeridian travel (Edwards et al. 2000), there may be sufficient finances for the 
athlete to travel well in advance of any competition or tournament so that jet lag 
symptoms subside prior to competition. It is not known whether jet lag interferes with 
training during this post-flight period to the extent that subsequent competitive 
performances are impaired. It is also not known at present whether jet lag increases 
the risk of injury in athletes preparing for competition. 
 
It is plausible that jet lag could affect the performances of world-class athletes who 
compete soon after travelling from another important competition, as part of an 
international tour. There is evidence from simulation studies and field studies that jet 
lag detrimentally affects subjective and simple performance measures, e.g. grip 
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strength, (Reilly et al. 2001). Nevertheless, the authors of a recent review on the 
effects of airline travel on sports performance were unable to locate a single study 
from which quantitative data could be extracted for externally-valid performance 
outcomes (Leatherwood and Dragoo, 2013). Therefore, despite the number of good 
quality laboratory simulation studies in which performance-relevant outcomes are 
measured in a repeated measures fashion (Leatherwood and Dragoo, 2013), the 
translation of evidence through steps one/two (Figure 1) is not particularly robust for 
world class athletes. 
 
For the occasional traveller, a clinical knowledge summary on jet lag has been 
published by the UK National Institute for Health and Care Medicine (NICE 2009). In 
this summary, the prevalence of clinically important jet lag symptoms is stated to be 
“unknown”. Therefore, while more knowledge is being derived about the 
mechanisms of circadian timing and these findings are attempted to be translated to 
jet lag treatments, the prevalence, symptomology and minimal clinically importance 
difference of jet lag symptoms seem unclear at present. 
 
3. Are the treatments suggested by animal and human simulations effective in 
reducing jet lag symptoms? 
In this section, published systematic reviews and evidence summaries on each 
proposed jet lag treatment will be summarised. However, before the evidence for the 
effectiveness of each treatment is discussed, there are some salient issues to 
consider regarding the translational value of animal models as well as which part of 
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the translational pathway (animal experiments, human experiments, real-world trials) 
tends to be emphasised in jet lag treatment research. 
 
3.1. Animal models and evidence translation in science 
It appears that the general translation of evidence from mechanistic animal 
experiments to the implementation of useful medical treatments is low. It has been 
reported that only about a third of highly-cited animal research is tested later in 
human trials. Only 8% of these clinical trials have been reported to successfully pass 
Phase I, which is when an intervention is examined for its safe use in human healthy 
volunteers (Mak et al 2014). Van der Worp et al. (2010) produced recommendations 
for the reporting of study quality when treatment strategies are being compared in 
animal models of disease (Table 1). These guidelines included the presence of 
sample size estimations, animal eligibility criteria, animal allocation concealment 
from main researchers, blinding and transparency regarding the flow of animals 
throughout the study, e.g., whether some animals had been excluded from the 
eventual data analysis. To date, the quality of animal experiments relevant to 
potential jet lag treatments has not been scrutinised against such standards. 
 
It is important to note that there are examples of health interventions arising from 
serendipitous discoveries through the course of basic research, e.g. Penicillin, 
although how reliant some chance discoveries have been on any preceding animal 
model research is often not clear (van der Worp et al., 2010). While such future 
discoveries are possible in the field of circadian biology, it is clear that many 
circadian biologists, who undertake laboratory-based experiments on animals, 
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currently cite the treatment of jet lag as an application of their findings. Therefore, 
this proposed application is open to scrutiny. 
 
3.2. Which translational step is emphasised in jet lag research? 
Once a proposed clinical treatment has successfully passed phases I-II, including 
studies on animals, the treatment should, be appraised for effectiveness, ideally 
using the gold-standard randomised controlled trial approach (Torgerson and 
Torgerson, 2008). A good quality randomised controlled trial that has robust 
components of participant allocation (both randomised and concealed), placebo 
control if the treatment is a drug, and reports the findings in accordance with the 
Consolidated Standards of Reporting Trials, is the ideal approach to quantifying 
effect sizes (Shulz et al. 2010). 
 
Other study designs, such as observational comparisons or non-comparator trials 
might provide useful information regarding jet lag. But it is difficult to accept any 
philosophical or practical drawbacks to undertaking a randomised controlled trial in 
the context of jet lag treatment. In Table 2, a list of perceived drawbacks of adopting 
a randomised controlled trial approach is presented alongside the appraisal of how 
relevant each perceived drawback is in the context of jet lag research. It is also 
relevant to question how many externally-valid and robust human randomised 
controlled trials on jet lag treatments have been undertaken and published compared 
with the number of laboratory-based simulations on animals and humans. 
 
In the Scopus database (1960-2014), a search for the term jet lag, and its variants, 
was completed in August 2014, and this resulted in a total of 1368 research outputs 
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(Figure 2). Three hundred and seventy-five of these outputs were labelled in Scopus 
as reviews. Seven hundred and twenty-two outputs were labelled as original articles 
or book chapters. One hundred and eighty of these articles involved an animal 
model. Importantly, only 1-2 publications per year appeared to be randomised 
controlled trials of jet lag treatments following real flights. Not all these studies might 
be robust randomised controlled trials. A formal systematic review of these studies 
(currently underway by the present authors) would also rate each of these trials for 
quality and adherence to the Consolidated Standards of Reporting Trials (Schulz et 
al. 2010), so the number of good quality trials could be extremely low. It is clear that 
the number of randomised controlled trials of treatment effectiveness is not mirroring 
the number of animal and human simulation studies on the efficacy of jet lag 
treatments (Figure 2). However, evidence syntheses of some of these trials have 
been undertaken, and these syntheses can now be discussed below categorised by 
each type of proposed treatment. 
 
3.3. Evidence that melatonin is a useful jet lag treatment 
In the sole Cochrane review dedicated to a potential treatment (melatonin) for jet lag 
following actual air travel, ten studies met the inclusion criteria of randomised trials 
with placebo or other medication and a primary outcome of subjective jet lag rating 
(Herxheimer and Petrie 2002). Eight of these studies were deemed by Herxheimer 
and Petrie (2002) to report positive effects of ingesting melatonin pills. Nevertheless, 
it can be seen in the subsequent meta-analysis undertaken by Herxheimer and 
Petrie (2002) that at least two of these eight studies did not report statistically 
significant effect sizes (see also Figure 4). For the 2-4 studies from which a common 
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outcome of overall jet lag rating (on a 0-100 scale) could be extracted by Herxheimer 
and Petrie (2002), melatonin mediated a pooled reduction of 19.5 (95%CI:  10.9-
28.1) and 17.3 (95%CI: 7.3-27.3) units for eastwards and westwards flights, 
respectively. These effect sizes are large when considered against the between-
subjects standard deviations reported by Herxheimer and Petrie (2002). 
Nevertheless, there are some important caveats to these data. 
 
First, it is relevant to question why two relatively large studies, which did not report 
any useful effects of melatonin on jet lag symptoms, were excluded by Herxheimer 
and Petrie (2002). In the first of these studies (Spitzer et al. 1999), the baseline 
measurements prior to an eastwards flight home across 6 time zones were obtained 
five days after the outward flight. This study was eventually excluded from the meta-
analyses even though it was one of the few studies to measure symptoms at 
baseline and adjust for them in the analyses. It is interesting that melatonin was 
reported by Spitzer et al. (1999) to have had negligible effects on the jet lag 
symptoms incurred by this short-stay (5 d at destination) travel schedule, which is 
typically followed by business travellers and tourists. Airline pilots may have even 
less than five days recovery between long-haul trans-meridian flights. The 
measurement tool employed by Spitzer et al. (1999) allowed many different types of 
subjective jet lag symptoms like tiredness and clumsiness to be recorded. 
Undoubtedly, if such subjective feelings are collected from any person, whether they 
have undertaken a flight or not, the summed values of these symptoms would not be 
zero. Unfortunately, only follow-up measures could be meta-analysed in the 
systematic review by Herxheimer and Petrie (2002) rather than the change in 
symptoms between follow-up and a pre-flight baseline measure.  
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Edwards et al. (2000) also recorded multiple symptoms of jet lag in their randomised 
controlled trial on melatonin. The questions were phrased in order to measure 
symptoms relative to how people might feel normally prior to the flight. Data were 
analysed in several ways, including approaches similar to those adopted by the other 
study authors whose study was included in the meta-analysis. Herxheimer and 
Petrie (2002) cited reporting problems for non-inclusion of this study. Nevertheless, 
Edwards et al. (2000) did attempt to analyse their data in accordance with previous 
studies which involved a global measure of jet lag. First, average ratings of jet lag 
were calculated over six post-flight days. No statistically significant differences 
between melatonin and placebo groups were found (P=0.741). Second, when the 
participant’s ratings of jet-lag recorded on day 6 solely were compared, no 
statistically significant group differences in jet lag ratings were found (P=0.833). 
 
In 2008, the systematic review on melatonin and jet lag by Herxheimer and Petrie 
(2002) was checked for any further studies using a database search, but none were 
located. Three studies have been published since 2001 In a recent clinical evidence 
review, Herxheimer (2014) concluded that melatonin reduces subjective ratings of jet 
lag on eastward and on westward flights compared with placebo. It was noted by 
Herxheimer (2014) that (i) the adverse effects of melatonin (drug eruption, allergic 
reaction) are uncertain and that epileptics and/or people taking an oral anticoagulant 
should not use melatonin without medical supervision, and (ii) that the quality control 
of melatonin products, particularly those purchased online, is suspect. 
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Using the statistical information reported in Spitzer et al. (1999) and Edwards et al. 
(2000), standardised effect sizes can be calculated for overall jet lag symptoms. 
These standardised effect sizes can also be calculated for the four studies meta-
analysed by Herxheimer and Petrie (2002) so that all six studies on eastwards flights 
can be considered together (Figure 3). It can be seen that reported effect sizes for 
melatonin have decreased since the first study was published in 1987. This particular 
study (Arendt et al. 1987) resulted in a remarkably large effect size of 1.5 standard 
deviations, which influences greatly the magnitude of the overall pooled effect size. 
The effect sizes for four of these six studies are not statistically significant. 
Therefore, this fresh analysis of the studies on melatonin questions its usefulness for 
reducing jet lag symptoms. It is clear that the effects reported in early studies from 
the same research group have not been replicated in subsequent studies. 
 
3.4. Evidence for other proposed treatments 
Light exposure schedules have been formulated from the results of laboratory-based 
studies (Waterhouse et al. 1997; Waterhouse et al. 2007; Sack 2010). Nevertheless, 
the first pilot randomised controlled trial of supplementary light treatment for 
alleviating real jet lag symptoms was published only last year (Thompson et al. 
2013). Prior to this study, only non-randomised and/or non-controlled investigations 
were available (Boulos et al. 2002; Lahti et al. 2007). Thompson et al. (2013) could 
not detect any clinically relevant effects of the supplementary light treatment on jet 
lag symptoms in a sample of elite female soccer players who flew, easterly, from 
North America to Portugal. The soccer players undertook their normal training habits 
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in the post-flight period prior to competing in an international tournament. The 
intervention participants sat approximately 50 cm from 2500 lux of supplementary 
bright light in their bedrooms for 45-60 min at a time-of-day predicted to accelerate 
circadian adjustment. Jet lag ratings were higher, not lower, in the supplementary 
light group on the first two post-flight days, but overall there were no clinically-
relevant differences between groups in all jet lag symptoms. In agreement with the 
data presented by Herxheimer and Petrie (2002), the inter-individual differences in 
the perception of jet lag symptoms were large with the between-subjects SD for 
overall jet lag rating being > 60%  of the sample mean values (on a 1-10 scale). 
 
Herxheimer (2014) could not locate any externally-valid randomised controlled trials 
on lifestyle/environmental interventions such as exercise, diet, avoiding alcohol, 
caffeine and sleep schedules. There is evidence from animal and human simulation 
experiments that these treatments may be useful in accelerating adjustment of 
circadian rhythms (Atkinson et al., 2007), but randomised controlled trials of these 
interventions following transmeridian travel appear, again, rare. Van Drongelen et al. 
(2014) recently completed the first randomised controlled trial of a complex 
intervention based on chronobiological theory and evidence from simulation studies. 
The intervention was designed to improve longer-term outcomes of fatigue and sleep 
quality in aircraft personnel undertaking frequent flying. Five hundred and two airline 
pilots were randomised to either an intervention or comparator group. Intervention 
participants could access a mobile device application, which provided tailored advice 
on various circadian zeirgebers (light, activity, meal times, etc). The control group 
was directed to a website with standard information about fatigue. Outcomes were 
measured through online questionnaires at baseline and at three and six months 
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after baseline. At the six month follow-up time-point, the intervention reduced self-
reported fatigue compared to the comparator group and improved some aspects of 
health-related behaviour such as physical activity, snacking behaviour as well as 
sleep quality, but not other measures of sleep (latency, duration, use of sleep-related 
medication). It would be interesting to examine similar interventions applied to 
reducing the shorter-term jet lag symptoms in the post-flight period following a one-
off flight. A freely available mobile device application together with online reporting of 
symptoms could be relatively easy to research. 
 
A recent clinical evidence statement included an appraisal of hypnotics 
(benzodiazepines; zopiclone; zolpidem; zaleplon) for reducing jet lag symptoms 
(Herxheimer, 2014). It was concluded that zopiclone or zolpidem, taken before 
bedtime on the first few nights after flying, may reduce the effects of jet lag by 
improving sleep quality and duration, although a formal meta-analysis of effect sizes 
was not undertaken. Herxheimer (2014) noted that hypnotics are associated with 
adverse effects including headache, dizziness, nausea, confusion, and amnesia. 
 
 
4. Does evidence from jet lag studies translate to population health? 
The effects of jet lag on longer-term health outcomes have also been studied in 
animal experiments. There are again difficulties in translating evidence from these 
studies to human health, i.e. through translational steps 1-3 (Figure 1). For example, 
a higher risk of cancer has been inferred from the results of experiments in which the 
light dark cycle in animal cages is advanced or delayed (e.g. Filipski et al. 2004). The 
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most recent and largest epidemiological study on humans has just been published 
(Hammer et al. 2014). Mortality was analysed in a pooled cohort of 93,771 aircraft 
cabin and cockpit crew members from 10 countries, with a mean follow-up period of 
21.7 years (20 million person-years). Overall mortality and cardiovascular-related 
mortality was substantially lower in both men and women, with standardised 
mortality rates of 0.46 to 0.73 being reported. Mortality from radiation-related cancers 
was also lower in men (standardised mortality rate: 0.73), but not different from the 
general population in women. Breast cancer mortality was unaffected in women, as 
was leukaemia and brain cancer in both men and women. Besides the obvious 
increased risk of death in an aircraft accident (which are obviously extremely rare 
events), the only substantial increase in risk in non-communicable disease was for 
malignant melanoma in men (standardised mortality rate: 1.57). The risk of AIDS of 
highly elevated in male cabin crew (standardised mortality rate of 14). 
 
There is a plausible mechanistic pathway between circadian disruption of the 
melatonin rhythm and cancer development (Leonardi et al., 2012). Nevertheless, 
there are alternative explanations for an increased risk of skin cancer in cabin and 
cockpit crew. Hammer et al. (2014) thought that aircraft windows provide adequate 
shielding of ultra-violet radiation exposure during the flight itself, and postulated that 
non-occupational factors, such as the opportunity for sunbathing, are more 
important. Hammer et al. (2014) cited the study by Dos Santos et al. (2013) who 
compared skin melanoma rates between British flight crew and air traffic controllers.  
The risks were similar between these samples, the strongest predictors of melanoma 
being light skin and sunbathing in both groups. Although these two occupational 
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group are not substantially different in social status and employment-related health 
requirements, Hammer et al. (2014) thought these factors could still play a role in 
explaining their own findings of decreased mortality from most causes in cabin and 
cockpit crew. 
 
 
5. Conclusions 
Despite the wealth of laboratory simulations of jet lag, and a penchant for some 
circadian biologists to mention jet lag treatment as a potential application of their 
findings, there is still a lack of well-controlled randomised controlled trials on jet lag 
treatments involving human participants travelling rapidly across world time zones. 
This lack of randomised controlled trials clouds the causal pathway between the 
intervention effects in animal and human simulations studies, and the intervention 
effects on real-world outcomes. In Figure 4, we present a simple model of this causal 
pathway in order to apply the probabilistic nature of reasoning to jet lag research 
(Howick et al. 2010). Each of the four basic components in the causal pathway are 
linked in a probabilistic chain. The intervention effects in one component depend on 
the correlation (r) with the intervention effects upstream in the mechanistic chain. 
The various correlations in the causal pathway can dilute the overall correlation 
between intervention effects in animal simulations and intervention effects on 
outcomes relevant to humans. For example, if each of the four correlations in Figure 
4 was a large r=0.7, the overall correlation between intervention effects in 
simulations and effects in real-world outcomes could be as low as 0.74 = 0.24. 
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In view of the above evidence that has been presented, and in conclusion, there is 
clearly not only a lack of good quality randomised controlled trials on jet lag 
treatments, but also a lack of reliable knowledge regarding the nature and clinical 
importance of jet lag in human travellers. As highlighted in section 3, more studies in 
the future could examine the post-flight effectiveness of all the potential 
chronobiological treatments identified from basic research, e.g., supplementary light, 
melatonin, etc., amalgamated into a complex intervention delivered through mobile 
devices. Importantly, there may be an aggregation of marginal gains from these 
treatments and interactions between treatments may be able to be explored 
(Durrand et al. 2014). Although challenging, such studies are needed to translate 
information adequately from the chronobiological bench to the real world. This would 
also help circadian biologists justify the clinical importance of their hard work and 
informative studies. 
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Table 1. A list of reporting requirements for appropriate quality of animal 
studies on health-related interventions. (van der Worp et al., 2010). 
 
Quality Aspect Explanation 
Sample size 
calculation: 
How the sample size was determined, and which assumptions 
were made regarding minimal important effect size and 
selected variance statistic. 
Eligibility criteria: Inclusion and exclusion criteria for eligibility 
Treatment allocation: The method by which animals were allocated to experimental 
groups. If this allocation was by randomisation, the method of 
randomisation and who undertook it. 
Allocation concealment The method used to implement the allocation sequence, and if 
this sequence was concealed until actual assignment. 
Blinding: Which investigators were blinded to the treatment allocation, 
and at which points in time during the study. 
Flow of animals: Flow of animals through each stage of the study, with particular 
reference to any animals excluded from the data analyses, with 
reasons. 
Control of 
physiological variables: 
Full details on which physiological variables were monitored 
and controlled. 
Control of study 
conduct: 
Whether a third party oversaw the conduct of the study. 
Statistical methods: Which statistical methods were used for which analysis 
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Table 2. Six typical arguments against the adoption of a randomised controlled 
trial approach for quantifying the effects of an intervention (Rosen et al. 2006). 
Each argument is considered in the context of research on treatments for jet lag 
following transmeridian travel. 
Critical 
argument 
Relevance 
to jet lag 
research 
Comments 
Withholding a 
treatment from 
the control 
group 
Not upheld The ethical concerns about some participants not 
receiving the jet lag treatment are low, given the low 
seriousness of jet lag symptoms compared with life-
threatening illnesses such as cancer. 
Jet lag is too 
complex an 
issue 
Not upheld Randomised controlled trials can be undertaken on 
both complex interventions and complex outcomes 
(Rosen et al. 2006). These factors do not preclude 
the undertaking of a randomised controlled trial for 
jet lag treatment. 
Randomised 
controlled trials 
are relevant 
only in the 
short-term 
Not upheld Jet lag is by its very nature transient and can be 
studied during the short post-flight follow-up period. 
Randomised controlled trials have also been 
undertaken on multiple periods of jet lag over several 
months (van Drongelen et al. 2014). 
Randomised 
controlled trials 
reduce  study 
generalizability 
Not upheld A study on jet lag following transmeridian travel is 
naturally real-world research outside the laboratory. 
Participants can, in theory, be drawn from any 
population who travel across time zones. 
Randomised 
controlled trials 
have no 
relevance to 
community 
health 
Not upheld Jet lag is not a community health issue, but can be 
experienced by any traveller who lives in any 
geographical community in the world. 
Randomised 
controlled trials 
are too 
Not upheld The costs of incorporating robust randomisation, 
blinding and allocation concealment are minimal. The 
main costs of a jet lag study are due to the travel 
itself, but it is possible for approaches like internet-
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expensive based research to keep costs down while optimising 
sample size and helping participants report their 
symptoms remotely. Studies in the past have also 
involved participants who travvled to an event or 
meeting. It might be expensive to measure circadian 
rhythms, such as those in melatonin and body 
temperature, during a trial, but refer to section 1 of 
this review where the potential disparity between 
these rhythms and overt jet lag symptoms is 
highlighted. 
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List of Figures 
 
Figure 1. The basic steps in translational physiology with respect to treatments for 
jet lag and the impact of jet lag on population health. Drawn from information 
presented by Seals (2013) and made specific to jet lag research. The translational 
pathway has three main steps. Findings from animal laboratory-based experiments 
first need to be reliably translated to inform human laboratory-based experiments (T1 
in the Figure). Then findings from human experiments need to reliably translated to 
good quality randomised controlled trials on humans after transmeridian flights so 
that clinical guidelines regarding jet lag treatment can be formulated (T2 in the 
Figure). Then this evidence needs to be reliably translated to public health policy on 
longer-term health problems and mortality (T3 in the Figure). Finally, findings from 
the latter epidemiological type studies can be translated to inform mechanistic 
experiments on animals (reverse translation). 
 
Figure 2. Results of a literature search using the SCOPUS database. The total 
number of studies that refer to jet lag and associated terms is plotted on a yearly 
basis. Also shown are the yearly records for those studies in which an animal model 
was referred to, and those studies that referred to a randomised controlled trial. 
 
Figure 3. A random-effects meta-analysis of standardised effect sizes from six 
studies on melatonin ingestion after westerly flights. The standardised effect sizes 
relate to an overall rating of jet lag relative to the standard deviation of the ratings. 
The standardised effect sizes from two studies (Spitzer et al. 1999; Edwards et al. 
2000) were calculated from reported test statistics and P-values relating to an overall 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
30 
 
rating of jet lag. These effect sizes were then analysed together with those 
standardised effect sizes calculated from four studies that were meta-analysed in a 
previous systematic review (Herxheimer and Petrie, 2002). Note how the effect sizes 
tend to decrease over the decades since the first and smallest study was published 
(Arendt et al., 1987). 
 
Figure 4. The probabilistic mechanistic chain between the effects of an intervention 
(I) on circadian rhythms of animals and humans studied in the laboratory and the 
effects of an intervention on externally valid outcomes (O) such as pilot- or athlete-
relevant performance measures. The robustness of this chain depends on how 
strong are the correlations (r) between the various links in the chain (Howick et al. 
2010). These correlations are difficult to quantify precisely but they serve to 
demonstrate how the overall link between basic and applied research is reliant on 
the strength of these correlations. The various correlations in the causal pathway can 
dilute the overall correlation between intervention effects in animal simulations and 
intervention effects on outcomes relevant to humans. For example, if each of the four 
correlations in Figure 5 was a large r=0.7, the overall correlation between 
intervention effects in simulations and effects in real-world outcomes could be as low 
as 0.74 = 0.24. 
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